Subscribe Become an Author Sign Up Log In

Artificial Intelligence


Tzager - A Smart AI Agent For Biomedical Research

   by Nikos Tzagarakis    396
Tzager - A Smart AI Agent For Biomedical Research

Tzager is an A.I. agent built for biomedicine research, drug discovery and personalized medicine, with the main features being Biochemical Analysis, Predictor Research/Models and Literature Review/Management. The difference with Tzager is that it is not just another deep learning algorithm trained to solve very specific problems, but the intelligence system with its own framework based on Causal Equations and Bayesian Networks.

3 Ways Big Data and Machine Learning Revolutionize Drug Discovery

   by Andrii Buvailo    10985
3 Ways Big Data and Machine Learning Revolutionize Drug Discovery

The Internet media is trending now with numerous mentions of “big data”, “machine learning” and “artificial intelligence” all together destined to revolutionize pharmaceutical and biotech industries and the way drugs are discovered. These new technologies are believed to make drug discovery cheaper, faster, and more productive.

But how is “magic” supposed to happen, after all?

AI For Commercial Life Sciences: 3 Trends You Can’t Ignore In 2020

   by Rasim Shah    252
AI For Commercial Life Sciences: 3 Trends You Can’t Ignore In 2020

As we enter a new decade, our belief in the the impact of Artificial intelligence (AI) is only getting stronger. Supporting the industry to drive the right drug to the right patient at speed is a huge responsibility that we take very seriously. Towards the end of the last decade we have seen great progress made within life sciences and the use of AI, but moving into 2020 the spotlight on commercial teams and gaining competitive advantage with AI will intensify.

ConstruQt – The Beginnings of the Chemical Data Revolution

   by Peter Jarowski    210
ConstruQt – The Beginnings of the Chemical Data Revolution

Chemical Data Has Problems

The state of data access, quality and dissemination in Chemistry is extremely poor - so poor that it is blocking advances in machine learning (ML) and artificial intelligence (AI), and also impeding research and development in traditional methods. The recent surge in AI skepticism is a direct consequence of years of over-hype and promises based on precarious data. Over-the-top expectation were offered without enough consideration for the data quality and volume required to train fancy algorithms. The old adage “^&$% in, ^&$% out” holds true (we can say ‘crap’ right?). This opinion is in line with recent statements by the CEO of Novartis, for example, who runs the second largest pharmaceutical company in the world, lamenting the difficulty in accessing quality datasets to make AI effective.

6th Digital Pathology & AI Congress

   by BiopharmaTrend    205
6th Digital Pathology & AI Congress

This Congress has a reputation for advancing pathology practice by exploring the implementation of digital pathology and artificial intelligence to advance patient care.

40+ presentations over two days offer the opportunity to discover more about the latest advances and applications of digital pathology. Learn how artificial intelligence and machine learning is being applied to primary diagnosis and clinical research and how the image-based information environment is transforming the laboratory.